No CrossRef data available.
Article contents
Abrupt Withdrawal of Antiparkinsonian Drugs in Chronic Schizophrenic Patients
Published online by Cambridge University Press: 29 January 2018
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Correspondence
- Information
- Copyright
- Copyright © Royal College of Psychiatrists, 1974
References
Chien, C., Dimascio, A. & Cole, J. O. (1974) Antiparkinsonian agents and depot phenothiazines. Amer. J. Psychiat., 131, 86–8.Google Scholar
El-Yousef, , Janowsky, D. S., Davies, J. M. & Sekerke, H. J. (1973) Reversal of antiparkinsonian drug toxicity by physostigmine. Amer. J. Psychiat., 130, 141–5.CrossRefGoogle ScholarPubMed
Fann, W. E., Lake, C. R., Gerber, C. J. & Mackenzie, J. M. (1974) Cholinergic suppression of tardive dyskinesia. Psychopharmacologia (Berl.), 37, 101–107.Google Scholar
Gerlach, J., Reisby, N. & Randrup, A. (1974) Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychopharmacologia (Berl.), 34, 31–5.Google Scholar
Klawans, H. L. (1973) The pharmacology of tardive dyskinesia. Amer. J. Psychiat., 130, 82–6.Google Scholar
Meyler, L. & Herxheimer, A. (1972) Side Effects of Drugs. Vol. vii. Amsterdam: Excerpta Medica.Google Scholar
Mindham, R. H. S., Gaind, R., Anstee, B. H. & Rimmer, L. (1972) Comparison of amantidine, orphenadrine and placebo in the control of phenothiazine-induced parkinsonism. Psychol. Med., 2, 406–413.Google Scholar
You have
Access
eLetters
No eLetters have been published for this article.